KEI Memo on U.S. Legislation to cap price increases on prescription drugs and to enhance the transparency of R&D costs
On April 30, 2019, KEI issued a memorandum to Congress concerning recent proposed measures to cap drug price increases and to increase the transparency of pharmaceutical research and development costs. Congress is currently considering several bills that touch on these… Continue Reading